Physician profile
Anthony P Lam
NPI 1659502839
$80,497.97
in general payments reported to CMS, 2019-2025
56 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,985 · 2020: $930 · 2021: $1,466 · 2022: $1,808 · 2023: $32K · 2024: $8,082 · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Consulting Fee: $17K · Food and Beverage: $8,637 · Travel and Lodging: $6,689 · Education: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,509.00 |
| Consulting Fee | $17,161.40 |
| Food and Beverage | $8,636.99 |
| Travel and Lodging | $6,689.25 |
| Education | $313.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $67,246.32 | 2019-2025 | |
| Janssen Biotech, INC. | $1,618.55 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Incyte Corporation | $1,533.78 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Exelixis INC. | $910.05 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $904.38 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Novartis Pharmaceuticals Corporation | $892.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $877.49 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Pfizer INC. | $755.57 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $503.26 | 2019-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Puma Biotechnology, INC. | $401.39 | 2019-2025 | |
| Genentech USA, INC. | $367.96 | 2019-2025 | Venclexta, Phesgo, Perjeta |
| Glaxosmithkline, LLC. | $354.96 | 2020-2025 | Zejula, Ojjaara, Jemperli |
| Celgene Corporation | $334.15 | 2019-2025 | Reblozyl |
| Amgen INC. | $312.00 | 2019-2023 | Lumakras, Kyprolis |
| Karyopharm Therapeutics INC. | $297.87 | 2020-2024 | Xpovio |
Show all 52 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.